Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 18:58 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
NCT05194735 · Alaunos Therapeutics · PHASE1/PHASE2 · terminated · last registry update 2026-11-09 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor halted enrollment on 14 Aug 2023 for business reasons after a Board review of funding needs and permanently discontinued TCR-T cell manufacturing. The study was not stopped for safety reasons.” | Open Targets' class: business administrative | Registry record, Alaunos Therapeutics |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL2RA in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-05-15Also stopped (terminated): Iovance Biotherapeutics, Inc., Lifileucel + LN-145 (NCT03645928)
- 2026-02-23Also stopped (withdrawn): Intima Bioscience, Inc., Fludarabine + Cyclophosphamide (NCT05566223)
- 2025-12-02Results posted on the registry: National Cancer Institute (NCI), IL-2 (Aldesleukin) + Cyclophosphamide (NCT05035407)
- 2025-12-02Also stopped (terminated): National Cancer Institute (NCI), IL-2 (Aldesleukin) + Cyclophosphamide (NCT05035407)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision